ExploreWatchlistsPricing
  1. JP-listed companies
  2. AnGes, Inc.
  3. Financials
  4. Stockholders' equity

AnGes, Inc. (4563)

Market cap
¥22.6B
P/E ratio
-2.2x
AnGes develops gene medicines and nucleic acid treatments, while providing genetic screening tests for rare disorders through its clinical research laboratory.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Dec 31, 20253,076+42.64%
Dec 31, 20242,157-91.74%
Dec 31, 202326,103-14.21%
Dec 31, 202230,425-21.25%
Dec 31, 202138,635+18.22%
Dec 31, 202032,680+171.08%
Dec 31, 201912,055+55.87%
Dec 31, 20187,734+113.55%
Dec 31, 20173,622-6.40%
Dec 31, 20163,869-8.34%
Dec 31, 20154,221-45.42%
Dec 31, 20147,734+118.27%
Dec 31, 20133,544

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat